Issue link: https://imageup.uberflip.com/i/1367494
34 | SUN LAKES LIFESTYLES | MAY 2021 | Happy Cinco de Mayo! Our amenities are finally opening! It is such a good feeling to be on our way back to normal. Our next meeting will be on Thurs., May 20 at 10 am. As of this writing we are not sure if the meeting will be by Zoom or in person. It's been a long time since we have seen each other. Let's hope we can meet in person. Members will be notified of the details by an email a few days prior to the meeting. For those of you who are new to our community, or if you are just looking for a caregiver support group, we also have entertainment, games and fun for your loved one while you attend an in-person meeting. Usually the meetings are held in the Multipurpose Room and we entertain the loved ones in the Arts & Crafts Room which is right next door. If you have any questions, would like to learn more about Memory Loss, or would like reading materials that we can loan you, call Diane, (951) 769-0130, Doug, (360) 840-5559 or Anne, (951) 845-8700. Remember we are here to help. I saw this article in the AARP Bulletin and thought I would share it with you. ALZHEIMER'S DRUGS SHOW PROMISE A new study by drug company Eli Lilly shows that an experimental drug may significantly slow cognitive decline in people with Alzheimer's disease. The 18 month study, which followed 272 people whose brain scans showed Alzheimer's, found that patients who took Donanemab had a 32 percent slower rate of decline than those who received a placebo. It's very encouraging because this is the first time a drug of its kind has had positive results in early-stage trials, says Lon Schneider, M.D., of the Keck School of Medicine at the University of Southern California. The drug works by targeting the hard plaque in the brain made from amyloid, a protein associated with Alzheimer's. Donanemab cleared a significant amount of the amyloid from users, Eli Lilly reports. That slowed the symptoms of the disease in those patients. The drugmaker says it will release more information on the drug tests soon. This isn't the only news Alzheimer's researchers are excited about. There are several new drugs close to getting FDA approval, or in development, that promise to really change the playing field for treatment of Alzheimer's disease, say Marwan Sabbagh M.D., director of the Lou Ruvo Center for Brain Health in Las Vegas. Richard Hodes, M.D., director of the National Institute on Aging, say that while NIA didn't fund the Eli Lilly trial, major public investment in Alzheimer's research makes possible that trial and many others testing a wide range of interventions. Caregiver Support Group